A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of major depressive disorder

Journal of Psychiatric Research

Volumn 47, Issue 7, 2013, Pages 944-954

  Targum, Steven D ^a,b   Wedel, Pamela C ^b   Robinson, Jill ^b   Daniel, David G ^c   Busner, Joan ^c   Bleicher, Leo S ^b   Rauh, Philip ^a   Barlow, Carrolee ^b  

^a Clintara LLC   (United States)

^b BrainCells Inc   (United States)

^c Bracket   (United States)

Author keywords

Centralized ratings; Major Depressive Disorder; Patient self ratings; Placebo response; Ratings reliability; Surveillance

Indexed keywords

BUSPIRONE; MELATONIN; PLACEBO;

ARTICLE; CENTRALIZED CLINICIAN RATING; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; HAMILTON SCALE; HUMAN; INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY 30; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PLACEBO EFFECT; PRIORITY JOURNAL; QUICK INVENTORY OF DEPRESSIVE SYMPTOMS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELIABILITY; SCORING SYSTEM; SELF-RATING DEPRESSION SCALE; SITE BASED RATING; TREATMENT OUTCOME;

EID: 84877153922     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.02.016     Document Type: Article

References (31)

1. Asgharnejad M., Targum S.D., Burch D., Gibertini M., Fava M. Surveillance strategies to improve study outcomes in a depression study. 52nd Annual NCDEU meeting, Phoenix AZ May 31, 2012.
2. Bland J.M., Altman D.G. Multiple significance tests: the Bonferroni method. British Medical Journal 1995, 310(6973):170.
3. Busner J., Daniel D.G., Montgomery S.A., Bartko J.J. Lower Chronbach's alpha at baseline than next visit in MDD studies with and without separate inclusionary scales. 52nd Annual NCDEU meeting, Phoenix, AZ July 1, 2012.
4. Chandler G., Targum S.D., Pollack M., Iosifescu D., Mischoulon D., Perlis R., et al. Validation of patients for a CNS trial of major depressive disorder. 49thAnnual NCDEU meeting, Hollywood, FL July 1, 2009.
5. DeBrota D., Demitrack M., Landin R., et al. A comparison between interactive voice response system-administered HAM-D and clinician-administered HAM-D in patients with major depressive episode. 39th Annual NCDEU meeting, Boca Raton, FL 1999.
6. Dunn J. Comparison of site-based versus centralized ratings in a clinical trial of generalized anxiety disorder. 163rd Annual meeting of the American Psychiatric Association, New Orleans May 24, 2010.
7. Fava M., Evins A.E., Dorer D.J., Schoenfeld D.A. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychotherapy and Psychosomatics 2003, 72:115-127.
8. Fava M., Targum S.D., Nierenberg A.A., Bleicher L.S., Carter T.A., Wedel P.C., et al. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. Journal of Psychiatric Research 2012, 46:1553-1563.
9. Feltner D.E., Kobak K.A., Crockatt J., et al. Interactive voice response (IVR) for patient screening of anxiety in a clinical drug trial. 41st Annual NCDEU meeting, Phoenix, AZ 2001.
10. Fleiss J.L. The design and analysis of clinical experiments 1986, John Wiley & Sons, New York, NY.
11. Guy W. ECDEU assessment manual for psychopharmacology 1976, DHEW Publication ADM-76-338.
12. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959, 32:50-55.
13. Kemp A.S., Schooler N.R., Kalali A.H., Alphs L., Anand R., Awad G., et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Schizophrenia Bulletin 2010, 36(3):504-509.
14. Khan A., Khan S.R., Walens G., Kolts R., Giller E.L. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003, 28:552-557.
15. Khan A., Kolts R.L., Rapaport M.H., Krishnan K.R.R., Brodhead A.E., Brown W.A. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychological Medicine 2005, 35:743-749.
16. Kobak K.A., Feiger A.D., Lipsitz J.D. Interview quality and signal detection in clinical trials. American Journal of Psychiatry 2005, 162:628.
17. Kobak K.A., Kane J.M., Thase M.E., Nierenberg A.A. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms?. Journal of Clinical Psychopharmacology 2007, 27(1):1-5.
18. Kobak K.A., Leuchter A., DeBrota D., Englehardt N., Williams J.B.W., Cook I.A., et al. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. Journal of Clinical Psychopharmacology 2010, 30:193-197.
19. Papakostas G.I., Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. European Neuropsychopharmacology 2009, 19:34-40.
20. Rush A.J., Giles D.E., Schlesser M.A., Fulton C.L., Weissenburger, Burns C. The inventory for depressive symptomatology (IDS): preliminary findings. Psychiatry Research 1986, 18(1):65-87.
21. Rush A.J. The inventory of depressive symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research 2000, 9(2):45-59.
22. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 2003, 54:573-583.
23. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33.
24. Stein D.J., Baldwin D.S., Dolberg O.T., Despiegel N., Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. Journal of Clinical Psychiatry 2006, 67(11):1741-1746.
25. Sysko R., Walsh B.T. A systematic review of placebo response in studies of bipolar mania. Journal of Clinical Psychiatry 2007, 8(8):1213-1217.
26. Targum S.D. Evaluating rater competency for CNS clinical trials. Journal of Clinical Psychopharmacology 2006, 26(3):308-310.
27. Targum S.D., Pollack M.H., Fava M. Re-defining affective disorders: relevance for drug development. CNS Neuroscience and Therapeutics 2008, 14:2-9.
28. Targum S.D., Little J.A., Lopez E., DeMartinis N., Rapaport M., Ereshefsky L. Application of external review for subject selection in a schizophrenia trial. Journal of Clinical Psychopharmacology 2012, 32(2):825-826.
29. Trivedi M.H., Rush A.J., Ibrahim H.M., Carmody T.J., Biggs M.M., Suppes T., et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological Medicine 2004, 34:73-82.
30. Walsh B.T., Seidman S.N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial and growing. Journal of the American Medical Association 2002, 287:1840-1847.
31. Williams J.B.W., Dunn J., Kobak K., Giller E., Curry L., Wilson P., et al. Placebo response assessed by site and remote blinded centralized raters in a GAD trial. 50thAnnual NCDEU meeting, Boca Raton, FL May 10, 2010.